CLRB vs. VNRX, ALTS, HYPD, INCR, GANX, OSTX, ANL, ELYM, INKT, and QNTM
Should you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include VolitionRx (VNRX), ALT5 Sigma (ALTS), Hyperion DeFi (HYPD), InterCure (INCR), Gain Therapeutics (GANX), OS Therapies (OSTX), Adlai Nortye (ANL), Eliem Therapeutics (ELYM), MiNK Therapeutics (INKT), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry.
Cellectar Biosciences vs. Its Competitors
Cellectar Biosciences (NASDAQ:CLRB) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.
VolitionRx has higher revenue and earnings than Cellectar Biosciences. VolitionRx is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 5.0% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 10.4% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cellectar Biosciences has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
In the previous week, Cellectar Biosciences had 8 more articles in the media than VolitionRx. MarketBeat recorded 10 mentions for Cellectar Biosciences and 2 mentions for VolitionRx. Cellectar Biosciences' average media sentiment score of 0.54 beat VolitionRx's score of 0.15 indicating that Cellectar Biosciences is being referred to more favorably in the media.
Cellectar Biosciences has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Cellectar Biosciences' return on equity.
Cellectar Biosciences currently has a consensus target price of $375.00, suggesting a potential upside of 7,209.94%. VolitionRx has a consensus target price of $3.50, suggesting a potential upside of 438.46%. Given Cellectar Biosciences' higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than VolitionRx.
Summary
VolitionRx beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.
Get Cellectar Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectar Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:CLRB) was last updated on 10/7/2025 by MarketBeat.com Staff
